Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials of its drug candidate AC01

STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announced that its portfolio company AnaCardio has completed the AC01-FE study in the U.S. and has also completed the first part of the Phase 1b/2a GOAL-HF1 clinical trial evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF).

The AC01-FE study was conducted in the US and evaluated the effects of food on the pharmacokinetics of AC01 in healthy volunteers. The study included 24 participants and AC01 was found to be safe and well tolerated under both fed and fasted conditions.